|
|
|
About us - Branches - Klerksdorp
|
|
|
| Staff |
[Back] |
| |
|
Organogram
|
 | Site Manager / Site Coordinator: HIV Prevention, Klerksdorp
Tanya Nielson
Pharmacist (B.Pharm & M.Sc)
Biosketch
|
| |
|
 | Deputy Director: Operations
Dr Kathryn Therese Mngadi
MBChB and Dip HIV Man(SA)
Biosketch
|
| |
|
 | Medical Officer: HIV Prevention, Klerksdorp
Dr Carien Lion-Cachet
MBChB, Masters Family Practice
Biosketch
|
| |
|
 | Medical Officer: HIV Prevention, Klerksdorp
Dr Pearl Selepe
MBChB
Biosketch
|
| |
|
 | Research Pharmacist / Study Coordinator: HIV Prevention, Klerksdorp
Surekha Persotam
B.Pharm
Biosketch
|
| |
|
 | Quality Assurance Officer: HIV Prevention, Klerksdorp
Marthinette Taljaard
B.Soc.Sc (Nursing)
Biosketch
|
| |
|
|
Our patients are our priority – their needs guide our research and treatment. We are careful to ensure that our ethics and patient – centered approach guide us at all times
Our Current work includes:
- Thibela TB ( research study to investigate the effectiveness of community wide isoniazid preventive therapy)
- Investigations of new TB Drugs/diagnostics/vaccines
- HIV prevention research
- HIV/TB care programme
- HIV testing and treatment service in correctional facilities
- Community Involvement Programmes
Community Advisory Boards (CABs):
The Klerksdorp site has established 2 Community Advisory Boards (adult and adolescent), a diverse group of volunteers, to provide community input into study design and local procedures. The Orkney site has a TB CAB .CAB members include community activists and/or professionals associated with HIV/AlDS and TB prevention and services delivery. Some of our CAB members are trial participants. A few have considerable scientific sophistication or relevant professional training, while others have no medical or scientific background but have a strong interest in HIV prevention. Together, the CABs fulfill the following roles:
- assist in the planning, development, and implementation of research
- assess community impact and ensure community concerns are considered
- serve as a voice for the community and study participants.
CAB members at our site help members of the general community to understand the science of HIV/AIDS and TB vaccines/drugs, as well as the methods of research and the clinical trials process. These discussions include candid conversations about fears and concerns related to government-sponsored research. Building strong relationships and a sense of trust between Aurum researchers and the community is crucial to the success of research.
Pipeline studies:
Virax:
This study will test a therapeutic vaccine for known HIV Infected individuals who may or may not be on ARV’s and who have a CD4 of > 350 cells/mm3, to ascertain if it can delay the progression to AIDS and time to ARV’s, as well as to ascertain if there will be a reduction in viral load which could result in the cessation of ARV’s.
We will need approximately 40 participants and plan to recruit them from the Jade Square CCMT clinic, from walk in VCT’s and possibly from peripheral DoH clinics with your approval.
We plan to start as soon as we have received approval from the NWDoH RC chair. The study has already been approved by the UKZN BREC, the MCC and the GMO; this is anticipated as early as June 2009.
Aeras:
This study will test a booster vaccine to BCG in HIV Infected individuals who are not on ARV’s and who have a CD4 of > 350 cells/mm3, to ascertain if the vaccine is safe, tolerable and effective.
Initially we will be looking at recruiting 25 participants for the first stage (intense safety), then another 450 for the second stage (safety and efficacy). We plan to plan to recruit them from the Jade Square walk in VCT’s from VCT campaigns conducted at local businesses and educational institutions, and possibly from campaigns at peripheral DoH clinics with your approval.
We plan to start as soon as we have received approval from the NWDoH RC chair. The study has already been approved by the Wits BREC, the MCC and the GMO; this is anticipated as early as June 2009.
ReMox:
This study will compare the standard TB regimen (HRZE) to two other regimens:
- One where Moxifloxacin replaces Ethambutol
- One where Moxifloxacin replaces Isoniazid
The aim to is to have a safe effective regimen that lasts only 4 months.
We will need approximately 150 participants and plan to recruit them from peripheral DoH clinics with your approval.
We plan to start in August as soon as we have received approval from the NWDoH RC chair. The study has already been approved by the Wits BREC, the MCC and the GMO.
VOICE:
This is a study to compare the safety and efficacy of a vaginal microbicide alone, to a combination of vaginal microbicide with an oral antiretroviral (Tenofovir), to placebo in approx 300 women.
We are still in early preparation for this study and are working to submit the package to the various regulatory bodies.
We hope to start in the first quarter of next year.
Site Manager:
Dr KT Mngadi
Ph: 018 406 4214
Cell: 082 337 0955
E-mail:
Fax 2 mail: 0865087616
Community Liaison Officer:
Mr NE Mngadi
Ph: 018 406 4235
Cell: 082 856 1145
E-mail:
Fax: 018 406 4240
|
|
|
|
 |
